BBIO News & Events

BridgeBio Pharma announced that positive results from PROPEL 3, the global Phase 3 study of oral infigratinib in children living with achondroplasia, were published as an original research article in the New England Journal of Medicine, NEJM. These data were also presented at the International Congress of Children's Bone Health, ICCBH, 2026 in a late-breaking oral presentation. The positive results shared in NEJM from PROPEL 3 include: PROPEL 3 successfully met the primary endpoint of change from baseline in annualized height velocity; PROPEL 3 successfully met the key secondary endpoint of change from baseline in height Z-score at Week 52; In a pre-specified exploratory analysis of the key secondary endpoint, oral infigratinib achieved the first statistically significant improvement in body proportionality against placebo in achondroplasia; Infigratinib was well-tolerated, with: No discontinuations related to study drug, No serious adverse events related to study drug, 3 cases of hyperphosphatemia, all mild, transient, asymptomatic, and not requiring dose reductions or discontinuations, No adverse events associated with inhibition of FGFR1 or FGFR2. Additional data presented at ICCBH showed infigratinib improved arm span vs. placebo by +0.37 SD, marking the first statistically significant improvement in arm span from a placebo-controlled achondroplasia trial

Spruce Biosciences announced the appointments of Eric Jordan as Vice President, Marketing and Tina Gullotta, CPA, as Vice President, Finance and Corporate Controller. Most recently, Jordan served as Marketing Team Lead at BridgeBio, where he led marketing and launch planning for encaleret, an investigational treatment for a rare endocrine disorder. Most recently, Gullotta served as Vice President, Finance at Frontier Medicines Corporation, where she led the Finance and Accounting organization and served as a strategic partner to the CEO, CFO, and Board.